Spravato vs. IV Ketamine: What Is the Difference?

Both act at the NMDA receptor. The Spravato labeling describes esketamine as a non-selective, non-competitive NMDA receptor antagonist and states that the mechanism by which it produces its antidepressant effect is unknown. Claims that one enantiomer is clinically superior go beyond what the labeling supports.

The route shapes the whole experience. With Spravato, the patient sprays the medication themselves under direct observation, using two devices for 56 mg or three for 84 mg with a five-minute rest between devices. [FDA label] With an infusion, a clinician places an IV and delivers the medication over a set period, with the ability to slow or stop it.

Neither route is inherently safer. They present different practical considerations: intranasal absorption can be affected by nasal conditions and requires the timing rules around nasal sprays and decongestants, while an infusion involves venous access and continuous administration.

Spravato’s labeling covers treatment-resistant depression in adults, as monotherapy or with an oral antidepressant, and depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior, with an oral antidepressant. [FDA label] The monotherapy option was added by FDA supplement approval on January 17, 2025. [FDA approval letter]

Off-label does not mean unstudied or improper. It does mean the regulatory scaffolding differs: no approved labeling for the indication, no REMS program, and generally no insurer policy built around an approved indication.

The Spravato indications rest on a registration trial program. Two examples: a randomized, double-blind, active-controlled trial of flexibly dosed esketamine with a newly initiated oral antidepressant in treatment-resistant depression, [Am J Psychiatry] and a randomized withdrawal trial of esketamine plus an oral antidepressant for relapse prevention in patients who had achieved stable remission or response. [JAMA Psychiatry] A separate program supported the acute suicidal ideation indication. [J Clin Psychiatry]

Intravenous racemic ketamine for depression has its own published literature, including randomized trials and systematic reviews, but no FDA-approved depression labeling and no single registration program defining a standard regimen. Protocols therefore differ between clinics.

These bodies of evidence were generated separately, with different designs, populations, endpoints, and comparators. That is precisely why they cannot be lined up to declare a winner — see the limits section below.

Spravato’s requirements are federal and identical everywhere: a certified setting, self-administration under direct observation, at least two hours of monitoring including blood pressure and respiratory status, and no driving until the next day. [SPRAVATO REMS]

Ketamine infusion practice has no equivalent federal program. Monitoring, staff presence, session length, and discharge criteria are determined by the treating clinician and clinic. That means standards can be equally rigorous — or not — and it is a reasonable thing to ask about directly.

Insurers generally write coverage policies around FDA-approved indications. That is the structural reason Spravato commonly has a written policy — typically with prior authorization — while ketamine infusions for depression, as an off-label use, are frequently excluded and paid out of pocket.

Neither pattern is universal. Some plans do not cover Spravato, or cover it with substantial cost sharing; some patients find coverage arrangements for infusions. See does insurance cover Spravato, and our pricing page for Innerbloom’s out-of-pocket ketamine services.

Cost comparisons between the two are only meaningful for a specific patient with a specific plan, which is why no figures are compared here.

Spravato uses fixed dose strengths — 56 mg or 84 mg — and a labeled schedule that steps down in frequency over the first weeks. [FDA label] The structure is predictable, and it is the same structure everywhere.

Infusion dosing is typically weight-based and can be adjusted by the clinician, including during a session. Series length and maintenance intervals vary by clinic rather than following a single labeled schedule.

Whether predictability or adjustability matters more depends on the patient and the clinical situation. Neither is an advantage in the abstract.

Factors that reasonably enter the conversation include:

• whether the patient's diagnosis and history fit an FDA-approved Spravato indication;
• medical history, including the labeled contraindications and blood pressure status;
• whether insurance coverage is available and what cost sharing would apply;
• the ability to attend frequent appointments and to arrange transportation;
• prior experience with either treatment;
• nasal conditions or other factors affecting a given route;
• the clinician's assessment of the monitoring appropriate for that patient.

Innerbloom Medical offers both Spravato and ketamine infusion services. Which is discussed is a clinical judgment made at an evaluation, not a default.

This page compares regulatory status, logistics, and payment — facts that can be stated. It does not compare effectiveness, speed of response, or safety between the two options, and that omission is deliberate.

Reasons for the caution:

• The two have not been compared head to head in a trial program designed to establish superiority for these indications.
• Indirect comparison across separate trials is confounded by differences in population, dose, route, endpoints, and comparator.
• Response varies substantially between individuals, so group-level findings do not predict an individual result.
• Ketamine infusion protocols are not standardized, so 'IV ketamine' does not describe one uniform treatment.

Any source claiming one option is definitively stronger, faster, safer, or more effective than the other is asserting more than the evidence supports.

The differences that matter in practice are structural, not a ranking. Spravato brings FDA-approved labeling, insurance policies built around that labeling, and a fixed set of safety requirements. Ketamine infusions bring dose flexibility and clinician-set protocols, usually without insurance coverage.

Because the two have not been directly compared in trials designed to answer “which is better,” the honest framing is fit rather than superiority: which option suits a particular person’s diagnosis, medical history, logistics, and coverage. That is a conversation with a clinician, not a conclusion from a table.